Sustained Release Microparticles Inhalation for Tuberculosis Treatment: Present Issues and Prospects

Abstract

Mycobacterium tuberculosis, the primary cause of tuberculosis in humans, is a transmissible airborne disease. One of the most significant medical advances of the 20th century was the development of medications to cure tuberculosis. It makes sense to create strategies for administering antitubercular medications orally, or through the respiratory system. The pulmonary route lowers systemic toxicity, necessitates a lower dose, and has instantaneous drug release, first pass hepatic metabolism, and side effects. Presently, the most prevalent patterns in study aim to offer the optimal dry powders in the appropriate fraction for inhalation, which can release the medication before it is eliminated through natural mechanisms.